Table 55: The US 15-Year Perspective for Pediatric Drugs andVaccines by Therapeutic Class - Percentage Share Breakdownof Dollar Sales for Pediatric Vaccines, Pediatric Hormones,Allergy & Respiratory Drugs, Anti-infective
Drugs, CNS Drugsand Other Pediatric Drugs Market for Years 2006, 2014 & 2020(includes corresponding Graph/Chart) III-23
located next to North Carolina's Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the pain, anti-infective
, and respiratory markets.
Modification of medical device surface with anti-infective
Key Topics Covered by "Competitor Analysis: Anti-Infective
This special report focuses on the market leaders for anti-infectives
and antimicrobials as well as the products in development anticipated to head this area in the years to come.
is a pharmaceutical company focused on the development and commercialization of anti-infective
drug products that fulfill substantial unmet medical needs in the treatment of infectious disease.
Garamycin is a trusted brand name and the product is a favorite among physicians who are looking for a single ingredient anti-infective
Collins will participate on the New and Powerful Anti-infectives
panel at the RBC Capital Markets 2007 Healthcare Conference.
To date, the most successful anti-infective
drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV).
Advances in understanding pathogenetic mechanisms and new antibody technologies have further contributed to a growing class of anti-infective
What's more, this study will examine the existing and developing anti-infective
agents targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid, yellow fever and onchocerciasis ("river blindness").
a biopharmaceutical company developing dermatological products, anti-infective
treatments and intranasal vaccines, announced today that it has closed a $22 million Series B financing round after recently securing an additional $10 million investment from NanoBio's majority shareholder Perseus, L.